Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from BCAL Diagnostics Limited ( (AU:BDX) ).
BCAL Diagnostics Limited has launched its BREASTEST plus™ in New South Wales, targeting breast cancer clinics in Sydney and Melbourne. The initial commercial rollout has been successful, with 107 tests sold and partnerships established with eight clinics and 33 breast specialists. The company has expanded its market access strategy to include general practitioners, enhancing doctor engagement and patient referrals. A strategic partnership with Cancer Care Associates has further increased access to the test. The recent policy update by BreastScreen Australia on breast density reporting supports the clinical uptake of BREASTEST plus™, highlighting its importance in early cancer detection where traditional mammography is less effective.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian company specializing in non-invasive breast cancer diagnostics. It focuses on providing innovative solutions like the BREASTEST plus™, aimed at improving breast cancer diagnosis, particularly for women with high-density breast tissue.
Average Trading Volume: 134,339
Technical Sentiment Signal: Sell
Current Market Cap: A$24.52M
Learn more about BDX stock on TipRanks’ Stock Analysis page.